{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:54Z","timestamp":1760144274088,"version":"build-2065373602"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.rmr.2022.11.085","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:04:32Z","timestamp":1670551472000},"page":"24-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibiteurs du r\u00e9cepteur de l\u2019IL-6\u00a0dans le traitement de la COVID-19\u00a0: que savons-nous\u00a0?"],"prefix":"10.1016","volume":"40","author":[{"given":"C.","family":"Lef\u00e8vre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Plocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Creux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-0742","authenticated-orcid":false,"given":"F.","family":"Philippart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2022.11.085_bib0630","series-title":"Advances in virus research","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-385885-6.00009-2","article-title":"Chapter 4 \u2013 coronavirus pathogenesis","author":"Weiss","year":"2011"},{"key":"10.1016\/j.rmr.2022.11.085_bib0635","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"Coronavirus as a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib0640","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib0645","unstructured":"In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases? [Internet]. The Centre for Evidence-Based Medicine. [cit\u00e9 6\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.cebm.net\/covid-19\/in-patients-of-covid-19-what-are-the-symptoms-and-clinical-features-of-mild-and-moderate-case\/."},{"issue":"5","key":"10.1016\/j.rmr.2022.11.085_bib0650","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/17512433.2021.1902303","article-title":"Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence","volume":"14","author":"Rahman","year":"2021","journal-title":"Expert Rev Clin Pharmacol.2021"},{"key":"10.1016\/j.rmr.2022.11.085_bib0655","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.autrev.2020.102536","article-title":"ACE2\u00a0at the centre of COVID-19\u00a0from paucisymptomatic infections to severe pneumonia","volume":"19","author":"Rivellese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rmr.2022.11.085_bib0660","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Revi"},{"key":"10.1016\/j.rmr.2022.11.085_bib0665","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.05738-11","article-title":"Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion","volume":"86","author":"Jensen","year":"2012","journal-title":"J Virol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0670","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.cytox.2020.100029","article-title":"SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the \u2018culprit lesion\u2019 of ARDS onset? What is there besides Tocilizumab?. SGP130Fc","volume":"2","author":"Magro","year":"2020","journal-title":"Cytokine X."},{"key":"10.1016\/j.rmr.2022.11.085_bib0675","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6\u00a0family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.rmr.2022.11.085_bib0680","first-page":"933","article-title":"Interleukine 17\u00a0et l\u2019inflammation chronique: de la d\u00e9couverte au ciblage th\u00e9rapeutique","volume":"200","author":"Miossec","year":"2016","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.rmr.2022.11.085_bib0685","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.rmr.2022.11.085_bib0690","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019\u00a0novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib0695","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0700","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0705","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2022.11.085_bib0710","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.toxicon.2017.10.016","article-title":"Exotoxins and endotoxins: inducers of inflammatory cytokines","volume":"149","author":"Cavaillon","year":"2018","journal-title":"Toxicon."},{"key":"10.1016\/j.rmr.2022.11.085_bib0715","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.rmr.2022.11.085_bib0720","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med."},{"issue":"5","key":"10.1016\/j.rmr.2022.11.085_bib1170","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019\u00a0in China","volume":"222","author":"Chi","year":"2020","journal-title":"J Infect Dis."},{"key":"10.1016\/j.rmr.2022.11.085_bib1175","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2022.11.085_bib1180","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019\u00a0pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Internal Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99\u00a0cases of 2019\u00a0novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib1190","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease","volume":"130","author":"Chen","year":"2019","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rmr.2022.11.085_bib1195","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/infdis\/jiab005","article-title":"Early differences in cytokine production by severity of coronavirus disease 2019","volume":"223","author":"Tjan","year":"2021","journal-title":"J Infect Dis."},{"key":"10.1016\/j.rmr.2022.11.085_bib1200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10875-020-00899-z","article-title":"Circulating levels of interleukin-6\u00a0and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis","volume":"41","author":"Udomsinprasert","year":"2021","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1205","first-page":"ciaa449","article-title":"Detectable serum SARS-CoV-2\u00a0viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19\u00a0patients","author":"Chen","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2022.11.085_bib1210","first-page":"218","article-title":"ESCAPE: an open-label trial of personalized immunotherapy in critically ill COVID-19\u00a0patients","volume":"14","author":"Karakike","year":"2022","journal-title":"JIN."},{"key":"10.1016\/j.rmr.2022.11.085_bib1215","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.chest.2020.06.006","article-title":"Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019","volume":"158","author":"Price","year":"2020","journal-title":"Chest."},{"key":"10.1016\/j.rmr.2022.11.085_bib1220","article-title":"Effect of tocilizumab on clinical outcomes at 15\u00a0days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"n84","author":"Veiga","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.rmr.2022.11.085_bib0860","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19\u00a0pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1230","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1235","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3\u00a0trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1035","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1040","doi-asserted-by":"crossref","first-page":"e0343","DOI":"10.1097\/CCE.0000000000000343","article-title":"Interleukin-6\u00a0trajectory and secondary infections in mechanically ventilated patients with coronavirus disease 2019\u00a0acute respiratory distress syndrome treated with interleukin-6\u00a0receptor blocker","volume":"3","author":"Vazquez Guillamet","year":"2021","journal-title":"Crit Care Explorations."},{"key":"10.1016\/j.rmr.2022.11.085_bib1240","doi-asserted-by":"crossref","first-page":"e02107","DOI":"10.1128\/aac.02107-21","article-title":"Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2022.11.085_bib1245","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s40121-021-00543-2","article-title":"Efficacy and safety of sarilumab in patients with COVID-19\u00a0pneumonia: a randomized, phase ill clinical trial (SARTRE study)","volume":"10","author":"Sancho-L\u00f3pez","year":"2021","journal-title":"Infect Dis Ther."},{"key":"10.1016\/j.rmr.2022.11.085_bib1250","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1093\/cid\/ciac153","article-title":"Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial","volume":"75","author":"Sivapalasingam","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2022.11.085_bib0725","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0730","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib0735","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19\u00a0Therapies (REACT) Working Group","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib0740","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0745","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rmr.2022.11.085_bib0750","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0755","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.rmr.2022.11.085_bib0760","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol Rep."},{"key":"10.1016\/j.rmr.2022.11.085_bib0765","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425255.2020.1822324","article-title":"Potential statin drug interactions in elderly patients: a review","volume":"16","author":"Damiani","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0770","doi-asserted-by":"crossref","first-page":"558898","DOI":"10.3389\/fimmu.2020.558898","article-title":"COVID-19: in the eye of the cytokine storm","volume":"11","author":"de la Rica","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0775","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19\u00a0and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell."},{"key":"10.1016\/j.rmr.2022.11.085_bib0780","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.rmr.2022.11.085_bib0785","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Jones","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmr.2022.11.085_bib0790","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajpath.2020.08.009","article-title":"Immunopathology of hyperinflammation in COVID-19","volume":"191","author":"Gustine","year":"2021","journal-title":"Am J Pathol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0795","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12890-020-01343-z","article-title":"Broncho-alveolar inflammation in COVID-19\u00a0patients: a correlation with clinical outcome","volume":"20","author":"Pandolfi","year":"2020","journal-title":"BMC Pulm Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0800","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19\u00a0era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0805","doi-asserted-by":"crossref","first-page":"e002285","DOI":"10.1136\/jitc-2020-002285","article-title":"IL-6 modulation for COVID-19: the right patients at the right time?","volume":"9","author":"Ascierto","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2022.11.085_bib0810","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.rmr.2022.11.085_bib0815","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13259","article-title":"Histopathology and genetic susceptibility in COVID-19\u00a0pneumonia","author":"von der Th\u00fcsen","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.rmr.2022.11.085_bib0820","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.imlet.2020.10.009","article-title":"Pulmonary vascular improvement in severe COVID-19\u00a0patients treated with tocilizumab","volume":"228","author":"Salvati","year":"2020","journal-title":"Immunol Lett"},{"key":"10.1016\/j.rmr.2022.11.085_bib0825","doi-asserted-by":"crossref","first-page":"110481","DOI":"10.1016\/j.mehy.2020.110481","article-title":"Looking beyond pulmonary disease in COVID-19: a lesson from patients with cystic fibrosis","volume":"147","author":"Manti","year":"2021","journal-title":"Med Hypotheses."},{"key":"10.1016\/j.rmr.2022.11.085_bib0885","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19\u00a0pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0850","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6\u00a0receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0840","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s40121-021-00543-2","article-title":"Efficacy and safety of sarilumab in patients with COVID19\u00a0pneumonia: a randomized, phase III clinical trial (SARTRE study)","volume":"10","author":"Sancho-L\u00f3pez","year":"2021","journal-title":"Infect Dis Ther."},{"key":"10.1016\/j.rmr.2022.11.085_bib0895","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib0830","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0835","doi-asserted-by":"crossref","first-page":"e0210721","DOI":"10.1128\/aac.02107-21","article-title":"Early use of sarilumab in patients hospitalized with COVID-19\u00a0pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.rmr.2022.11.085_bib0845","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1093\/cid\/ciac153","article-title":"Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial","volume":"75","author":"Sivapalasingam","year":"2022","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2022.11.085_bib0855","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(21)00315-5","article-title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial.","volume":"4","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.rmr.2022.11.085_bib0865","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs. usual care in adults hospitalized with COVID-19\u00a0and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0870","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19\u00a0pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0875","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0880","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3\u00a0trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0890","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19\u00a0pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0900","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15\u00a0days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.rmr.2022.11.085_bib0905","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19\u00a0pneumonia: a randomized clinical trial","volume":"47","author":"Rosas","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0910","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2022.2168","article-title":"High-dose dexamethasone and oxygen support strategies in Intensive Care Unit patients with severe COVID-19\u00a0acute hypoxemic respiratory failure: the COVIDICUS randomized clinical trial","volume":"182","author":"Bouadma","year":"2022","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0915","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-2600(21)00139-9","article-title":"Interleukin-6\u00a0receptor blockade in patients with COVID-19: placing clinical trials into context","volume":"9","author":"Angriman","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0920","doi-asserted-by":"crossref","first-page":"2102523","DOI":"10.1183\/13993003.02523-2021","article-title":"Effect of interleukin-6\u00a0receptor antagonists in critically ill adult patients with COVID-19\u00a0pneumonia: two randomised controlled trials of the CORIMUNO-19\u00a0Collabortive Group","volume":"60","author":"Hermine","year":"2022","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2022.11.085_bib0925","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.eclinm.2022.101362","article-title":"Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19\u00a0pneumonia: a randomised clinical trial from the CORIMUNO-19\u00a0study group","volume":"46","author":"Hermine","year":"2022","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.rmr.2022.11.085_bib0930","unstructured":"Rezaei S, Fatemi B, Karimi Majd Z, Minaei H, Peikanpour M, Anjidani N, et al. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. Expert Rev Clin Immunol.:1-13."},{"key":"10.1016\/j.rmr.2022.11.085_bib0935","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6\u00a0antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"WHO Rapid Evidence Appraisal for COVID-19\u00a0Therapies (REACT) Working Group","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib0940","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/22221751.2022.2059405","article-title":"Clinical efficacy and safety of interleukin-6\u00a0receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.rmr.2022.11.085_bib0945","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/a-1336-2371","article-title":"Efficacy and safety of tocilizumab for coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis","volume":"71","author":"Hariyanto","year":"2021","journal-title":"Drug Res (Stuttg)."},{"key":"10.1016\/j.rmr.2022.11.085_bib0950","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"76","author":"Khan","year":"2021","journal-title":"Thorax."},{"key":"10.1016\/j.rmr.2022.11.085_bib0955","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.26509","article-title":"Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis","volume":"93","author":"Aziz","year":"2021","journal-title":"J Med Virol."},{"key":"10.1016\/j.rmr.2022.11.085_bib0960","doi-asserted-by":"crossref","unstructured":"C Z, Yf H.J., W, et al. Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials. Front Public Health. 2021; Sep 28;9:729559","DOI":"10.3389\/fpubh.2021.729559"},{"key":"10.1016\/j.rmr.2022.11.085_bib0965","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.3390\/ijerph18179149","article-title":"Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000\u00a0covid-19\u00a0pneumonia patients during the first eight months of the pandemic","volume":"18","author":"Mahroum","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"10.1016\/j.rmr.2022.11.085_bib0970","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.3390\/jcm10214935","article-title":"The use of tocilizumab in patients with COVID-19: a systematic review, meta-analysis and trial sequential analysis of randomized controlled studies","volume":"10","author":"Maraolo","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0975","first-page":"e2022014","article-title":"Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs","volume":"93","author":"Mutua","year":"2022","journal-title":"Acta Biomed."},{"key":"10.1016\/j.rmr.2022.11.085_bib0980","doi-asserted-by":"crossref","first-page":"e0248132","DOI":"10.1371\/journal.pone.0248132","article-title":"Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (the LIVING Project)","volume":"16","author":"Juul","year":"2021","journal-title":"PLoS One."},{"key":"10.1016\/j.rmr.2022.11.085_bib0985","doi-asserted-by":"crossref","first-page":"107602","DOI":"10.1016\/j.intimp.2021.107602","article-title":"The effect of tocilizumab on COVID-19 patient mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Wt","year":"2021","journal-title":"International immunopharmacology"},{"key":"10.1016\/j.rmr.2022.11.085_bib0990","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jim-2021-002001","article-title":"Tocilizumab in patients hospitalized with COVID-19\u00a0pneumonia: systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Gupta","year":"2022","journal-title":"J Investig Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib0995","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00134-021-06416-z","article-title":"Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials","volume":"47","author":"Snow","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1000","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/phar.2627","article-title":"Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis","volume":"41","author":"Rubio-Rivas","year":"2021","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.rmr.2022.11.085_bib1005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/qjmed\/hcab142","article-title":"Tocilizumab in the treatment of COVID-19-a meta-analysis","volume":"114","author":"Avni","year":"2021","journal-title":"QJM."},{"key":"10.1016\/j.rmr.2022.11.085_bib1010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jiph.2021.06.004","article-title":"Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"14","author":"Pinzon","year":"2021","journal-title":"J Infect Public Health."},{"key":"10.1016\/j.rmr.2022.11.085_bib1015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00228-021-03087-z","article-title":"The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials","volume":"77","author":"Kow","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1020","article-title":"Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19\u00a0treated with corticosteroids: a systematic review and meta-analysis","author":"Albuquerque","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2022.11.085_bib1025","first-page":"CD013881","article-title":"Interleukin-6\u00a0blocking agents for treating COVID-19: a living systematic review","volume":"3","author":"Ghosn","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.rmr.2022.11.085_bib1030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00408-021-00451-9","article-title":"Tocilizumab in hospitalized patients with COVID-19: a meta analysis of randomized controlled trials","volume":"199","author":"Selvaraj","year":"2021","journal-title":"Lung."},{"key":"10.1016\/j.rmr.2022.11.085_bib1045","unstructured":"Somers EC, Eschenauer GA, Troost JP, Golob L, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.:27."},{"key":"10.1016\/j.rmr.2022.11.085_bib1050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10875-020-00911-6","article-title":"Tocilizumab for severe worsening COVID-19\u00a0pneumonia: a propensity score analysis","volume":"41","author":"Roumier","year":"2021","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130-Src-YAP module links inflammation to epithelial regeneration","volume":"519","author":"Taniguchi","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.rmr.2022.11.085_bib1060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00134-021-06573-1","article-title":"Dexamethasone 12\u00a0mg versus 6\u00a0mg for patients with COVID-19\u00a0and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2\u00a0trial","volume":"48","author":"Granholm","year":"2022","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br J Haematol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2021.11121","article-title":"IL-6\u00a0receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how?","volume":"326","author":"Matthay","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib1075","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMe2032071","article-title":"Tocilizumab for COVID-19\u00a0\u2013\u00a0the ongoing search for effective therapies","volume":"383","author":"Huang","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.rmr.2022.11.085_bib1080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-2600(21)00127-2","article-title":"IL-6\u00a0blockade for COVID-19: a global scientific call to arms","volume":"9","author":"Murthy","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1085","first-page":"e0395","article-title":"Early tocilizumab dosing is associated with improved survival in critically ill patients infected with severe acute respiratory syndrome coronavirus-2","volume":"3","author":"Petrak","year":"2021","journal-title":"Crit Care Explor."},{"key":"10.1016\/j.rmr.2022.11.085_bib1090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2\u00a0variants to immune sera elicited by vaccines after boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.rmr.2022.11.085_bib1095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.semdp.2019.04.006","article-title":"Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella","volume":"36","author":"Bradley","year":"2019","journal-title":"Semin Diagn Pathol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology."},{"key":"10.1016\/j.rmr.2022.11.085_bib1105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7861\/clinmedicine.4-2-152","article-title":"Severe acute respiratory syndrome (SARS): a review","volume":"4","author":"Vijayanand","year":"2004","journal-title":"Clin Med (Lond)."},{"key":"10.1016\/j.rmr.2022.11.085_bib1110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-med-051215-031152","article-title":"Middle East respiratory syndrome: emergence of a pathogenic human coronavirus","volume":"68","author":"Fehr","year":"2017","journal-title":"Annu Rev Med."},{"key":"10.1016\/j.rmr.2022.11.085_bib1115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/path.4454","article-title":"Molecular pathology of emerging coronavirus infections","volume":"235","author":"Gralinski","year":"2015","journal-title":"J Pathol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1120","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314\u00a0cases from the Chinese Center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib1125","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19\u00a0in New York City: a prospective cohort study","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.rmr.2022.11.085_bib1130","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591\u00a0patients infected with SARS-CoV-2\u00a0admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2022.11.085_bib1135","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019\u00a0pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Internal Med"},{"key":"10.1016\/j.rmr.2022.11.085_bib1140","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/eji.201243018","article-title":"Interleukin-6\u00a0limits influenza-induced inflammation and protects against fatal lung pathology","volume":"43","author":"Lauder","year":"2013","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6\u00a0as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"key":"10.1016\/j.rmr.2022.11.085_bib1150","doi-asserted-by":"crossref","first-page":"2200803","DOI":"10.1183\/13993003.00803-2022","article-title":"Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline","volume":"60","author":"Roche","year":"2022","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2022.11.085_bib1155","doi-asserted-by":"crossref","unstructured":"RECOVERY collaborative group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400(10349):359-368.","DOI":"10.1016\/S0140-6736(22)01109-6"},{"key":"10.1016\/j.rmr.2022.11.085_bib1160","unstructured":"Interleukin-6\u00a0Inhibitors [Internet]. COVID-19\u00a0Treatment Guidelines. [cit\u00e9 5\u00a0sept 2022]. Disponible sur: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/interleukin-6-inhibitors\/."},{"key":"10.1016\/j.rmr.2022.11.085_bib1165","unstructured":"ROACTEMRA (tocilizumab) (Covid-19) [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 5\u00a0nov 2022]. Disponible sur: https:\/\/www.has-sante.fr\/jcms\/p_3318928\/fr\/roactemra-tocilizumab-covid-19."}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522004600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522004600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:24:09Z","timestamp":1760106249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842522004600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0761842522004600"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2022.11.085","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiteurs du r\u00e9cepteur de l\u2019IL-6\u00a0dans le traitement de la COVID-19\u00a0: que savons-nous\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2022.11.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}